实朴检测 reported revenue of ¥0.16B for the period ended 2026-06-30, -4.3% year on year. Net income was ¥-0.00B, a -1.4% net margin on a 29.7% gross margin. The largest revenue line is 土壤和地下水检测 at 36% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.16B | -4.3% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥-0.00B | — |
| Net income | ¥-0.00B | — |
| Gross margin | 29.7% | Net margin -1.4% |
| Revenue Q/Q | +44.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 土壤和地下水检测 | ¥0.06B | 35.6% |
| 钻井采样 | ¥0.03B | 17.6% |
| 技术咨询服务 | ¥0.02B | 14.3% |
| 修复服务 | ¥0.01B | 8.6% |
| 媒介代理和全案营销服务业务 | ¥0.01B | 8.2% |
| 农业与环保 | ¥0.01B | 6.3% |
| 食品安全检测 | ¥0.01B | 5.4% |
| 水质和气体检测 | ¥0.00B | 2.2% |
| 其他 | ¥0.00B | 1.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.11B | 70.3% |
| R&D | ¥0.01B | 6.5% |
| SG&A | ¥0.04B | 28.1% |
| Tax & other | ¥0.00B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥1.08B |
| Total liabilities | ¥0.47B |
| Shareholders' equity | ¥0.61B |
| Equity / assets | 56.8% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | 3071% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
纽泰格 ・ 泓博医药 ・ 荣信文化 ・ 飞沃科技 ・ 盛帮股份 ・ 五洲医疗 ・ 华康洁净 ・ 和顺科技 ・ 瑞泰新材 ・ 普瑞眼科 ・ 宏源药业 ・ 杰创智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies